CryoLife, Inc - NYSE: CRY
CryoLife is one of the world’s contemporary medical device companies providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers and implantable end-stage renal disease access grafts for the repair of complex cardiac and vascular reconstruction surgeries.
Since the Company’s inception in 1984, it is estimated that its products and tissues have been implanted in over 1,000,000 patients worldwide.
Headquartered in suburban Atlanta, Georgia, U.S.A., CryoLife has sales and marketing centers in Great Britain, Singapore, Argentina, and Germany and representation in over 75 countries worldwide.
The firm’s 500 employees hail from eleven countries and speak seventeen languages.
CryoLife’s staff includes four full-time physicians and eight Ph.D.s with disciplines in chemical engineering, biomedical engineering, biochemistry, protein chemistry and organic chemistry.